Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1813 results
April 2022
-
Tackling the health toll of climate change
-
Media ReleaseNovartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancersEuropean Medicines Agency validated MAAs for tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indicationsSubmissions based on data from Phase III RATIONALE…
-
Media ReleaseSandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening…
-
Media ReleaseFDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is…
-
Media ReleaseNovartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosisPhase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
-
Media ReleaseNovartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facilityClearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
-
Key ReleaseNovartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivityAd hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of…
-
Key ReleaseNovartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhere ProduktivitätAd-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase…
March 2022
-
Media ReleaseNovartis announces European Commission approval of Beovu® for people living with diabetic macular edemaDiabetic macular edema (DME) is a leading cause of blindness in adults in developed countries; unmet needs in DME include improving fluid resolution in the retina and addressing the burden of…
-
Media ReleaseNovartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host diseaseCHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD)…
-
Media ReleaseNovartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in EuropePositive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial…
-
Understanding hidradenitis suppurativa through Jasmine’s eyes
Pagination
- ‹ Previous page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- …
- 152
- › Next page